Aardvark Therapeutics, Inc. Common Stock
NASDAQ Global SelectTotal Valuation
Aardvark Therapeutics, Inc. Common Stock carries a market capitalization of 133.06M, placing it among publicly traded companies globally. Its enterprise value stands at -8.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 133.06M |
| Enterprise Value | -8.86M |
Share Statistics
Aardvark Therapeutics, Inc. Common Stock currently has 21.82M shares outstanding.
| Shares Outstanding | 21.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.60 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | -1.33 |
| P/OCF Ratio | -1.33 |
Financial Position
Aardvark Therapeutics, Inc. Common Stock maintains a current ratio of 8.06, meaning it holds 8.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.06 |
| Quick Ratio | 7.86 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -54.67 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Aardvark Therapeutics, Inc. Common Stock's stock has declined approximately -49.33333% over the past 52 weeks. The 50-day moving average sits at 4.87, while the 200-day moving average is 8.99.
| Beta (5Y) | N/A |
| 52-Week Price Change | -49.33333% |
| 50-Day Moving Average | 4.87 |
| 200-Day Moving Average | 8.99 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -74.68M, while operating income came in at -74.72M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -74.72M |
| Pretax Income | -69.87M |
| Net Income | -69.87M |
| EBITDA | -74.68M |
| EBIT | -74.72M |
| Earnings Per Share (EPS) | -3.21 |
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock holds 91.20M in cash and equivalents against 336,000.00 in total debt, resulting in a net debt position of -62.44M. Total book value stands at -137.51M, with working capital of 81.98M providing operational flexibility.
| Cash & Cash Equivalents | 91.20M |
| Total Debt | 336,000.00 |
| Net Debt | -62.44M |
| Equity (Book Value) | -137.51M |
| Book Value Per Share | -6.32 |
| Working Capital | 81.98M |
Cash Flow
Aardvark Therapeutics, Inc. Common Stock produced -61.65M in operating cash flow over the past twelve months. After subtracting -95,000.00 in capital expenditures, free cash flow totaled -61.75M - equivalent to -2.84 per share.
| Operating Cash Flow | -61.65M |
| Capital Expenditures | -95,000.00 |
| Free Cash Flow | -61.75M |
| FCF Per Share | -2.84 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.46 |
| FCF Yield | -75.07 |
Scores
Aardvark Therapeutics, Inc. Common Stock posts an Altman Z-Score of 0.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.78 |